GE Healthcare has announced the opening of a biotechnology manufacturing centre at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, in Stevenage, UK.
In the first half of 2019, the centre will start producing a fibre-based purification platform, which has the potential to significantly improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies and viral vectors.
“This technology will bring real efficiency and productivity advantages for biopharmaceutical manufacturers as they move towards integrated, connected or continuous operations,” says Olivier Loeillot, general manager, BioProcess at the firm.
“The fibre-based chromatography technology developed and manufactured in Stevenage will extend GE Healthcare’s start-to-finish bioprocess purification portfolio.”
Biopharmaceuticals, such as monoclonal antibodies, are the world’s fastest-growing class of medicine. The global market for biopharmaceuticals is estimated at more than $200 billion, and the market is continuing to grow at around 8% annually.